

Resource Summary Report

Generated by ASWG on Aug 10, 2026

APC anti-mouse CD137

RRID:AB_2564297

Type: Antibody

Proper Citation

BioLegend Cat# 106110, RRID:AB_2564297

Antibody Information

URL: http://antibodyregistry.org/AB_2564297

Proper Citation: BioLegend Cat# 106110, RRID:AB_2564297

Target Antigen: CD137

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse CD137

Description: This monoclonal targets CD137

Target Organism: mouse

Clone ID: Clone 17B5

Antibody ID: AB_2564297

Vendor: BioLegend

Catalog Number: 106110

Alternative Catalog Numbers: 106109

Record Creation Time: 20250819T230525+0000

Record Last Update: 20250820T041510+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse CD137.

No alerts have been found for APC anti-mouse CD137.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Kourtesakis A, et al. (2026) A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct. Molecular therapy. Oncology, 34(1), 201134.

Salazar-Cavazos E, et al. (2026) Stochasticity in cancer immunotherapy stems from rare but functionally critical Spark T cells. Cell, 189(4), 1074.

Obenaus M, et al. (2026) T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells. bioRxiv : the preprint server for biology.

Uraki R, et al. (2025) An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant. EBioMedicine, 117, 105794.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Lim RJ, et al. (2024) CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell reports. Medicine, 5(4), 101479.

Gutierrez E, et al. (2023) An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med (New York, N.Y.), 4(5), 326.

Martin AL, et al. (2023) Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. Cancer immunology, immunotherapy : CII, 72(6), 1445.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer, 11(3).

Blomberg OS, et al. (2023) IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer cell, 41(1),

Maruhashi T, et al. (2022) Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. *Immunity*, 55(5), 912.

Wang C, et al. (2021) Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. *Cell reports*, 37(8), 110021.

Hanna BS, et al. (2021) Interleukin-10 receptor signaling promotes the maintenance of a PD-1^{int} TCF-1⁺ CD8⁺ T cell population that sustains anti-tumor immunity. *Immunity*, 54(12), 2825.

Sadik A, et al. (2020) IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, 182(5), 1252.

Jin J, et al. (2020) CD137 Signaling Regulates Acute Colitis via RALDH2-Expressing CD11b-CD103⁺ DCs. *Cell reports*, 30(12), 4124.

Etxeberria I, et al. (2019) Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8⁺ T Cells. *Cancer cell*, 36(6), 613.